In conclusion, the insights gained from this study offer valuable groundwork for future investigations into a potential therapeutic role for PP13 in treating preeclampsia, a condition that affects approximately 8% of women worldwide and is still without a definitive cure. Here, LGALS13 is linked to preeclampsia.